ADPT vs CVAC: fair value comparison
Adaptive Biotechnologies Corporation and CureVac N.V. · Updated 2026-10-19
ADPT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CVAC reports in EUR, so no same-currency fair-value verdict is published for it. Within Healthcare, ADPT currently ranks higher by quality score.
| ADPT | CVAC | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $24.02 | $4.66 |
| 12-month range | $12.41–$29.84 | $4.12–$5.49 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #141 of 301 Healthcare | #142 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | High | — |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | — |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: ADPT fair value analysis · CVAC fair value analysis